AcelRx Pharmaceuticals (ACRX) Posts Narrower than Expected Q4 Loss of 33c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts ACRX Hot Sheet
Join SI Premium – FREE
AcelRx Pharmaceuticals (NASDAQ: ACRX) reported Q4 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39).
For earnings history and earnings-related data on AcelRx Pharmaceuticals (ACRX) click here.
For earnings history and earnings-related data on AcelRx Pharmaceuticals (ACRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JetBlue shares jump on Q3 results and 2027 outlook
- Bladex (BLX) Reports Q3 EPS of $1.48
- Park National Corp. (PRK) Tops Q3 EPS by 6c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
